Drugs / ALLO-ASC-TI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02131077 | Jan → Oct 2014 | epicondylitis | Anterogen Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALLO-ASC-TI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02131077 ↗ |
| Modality | Cell therapy | “allogeneic adipose-derived stem cells (ALLO-ASC)” NCT02131077 ↗ |